Cohort Study to Evaluate Fetal and Infant Outcomes Following Maternal Exposure to Bimekizumab during Pregnancy

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000001042
• Study ID:
  1000001042
• Official title and acronym:
  Cohort Study to Evaluate Fetal and Infant Outcomes Following Maternal Exposure to Bimekizumab during Pregnancy
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  No information provided.
• Study status:
  Planned

Study timelines

Date when funding contract was signed

Planned:21/12/2022

Actual:21/12/2022

Study start date

Planned:01/09/2026

Date of final study report

Planned:31/12/2035

Sources of funding

Pharmaceutical company and other private sector 

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

PS0037